SIX: OBSN

Swiss biopharmaceutical company ObsEva SA (SIX: OBSN) has announced that it has regained full rights to its pipeline candidate, nolasiban, after the termination of a previous license agreement with China-based Yuyuan Biological Technology. Nolasiban’s Profile and Its Importance in IVF TreatmentNolasiban is an oral oxytocin receptor antagonist that plays a…